NCT00309140View on ClinicalTrials.gov

An Open Label Study of Oral Enzastaurin in Participants With Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
NeoplasmsCancer
Interventions
DRUG

enzastaurin

500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity

Trial Locations (1)

85351

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00309140 - An Open Label Study of Oral Enzastaurin in Participants With Cancer | Biotech Hunter | Biotech Hunter